Literature DB >> 1354978

Subacute toxicity of pentavalent antimony compounds in rats.

A alKhawajah1, E B Larbi, S Jain, Y al-Gindan, A Abahussain.   

Abstract

A subacute toxicity study of pentavalent antimony (Sb) compounds, sodium stibogluconate (SSG) and meglumine antimoniate (MA) was carried out in rats. Three groups of 10 rats each were treated with saline (control group), 300 mg Sb kg-1 d-1 or 900 mg Sb kg-1 d-1 of SSG for 30 d. A parallel study of similar type was conducted for MA. Compared with controls, drug-treated rats showed an impairment of feeding habits and retardation of weight gain (P less than 0.01) during the treatment period. In both SSG- and MA-treated rats there was a dose-related reduction in haemoglobin concentration (P less than 0.001), and hematocrit (P less than 0.001). Red cell count was reduced in SSG-treated rats only. Both drugs, however, significantly raised the white cell count (P less than 0.05). These changes were more pronounced with SSG them with MA. There was no change in MCV, MCH and MCHC. SSG, 900 mg Sb kg-1 d-1, significantly raised AST (P less than 0.005), ALT (P less than 0.01) and alkaline phosphatase activity (P less than 0.01). SSG-treated rats also had raised BUN (P less than 0.01) and creatinine (P less than 0.001), but no significant change in bilirubin levels. MA significantly raised AST (P less than 0.01), ALT (P less than 0.01), BUN (P less than 0.001) and serum creatinine levels (P less than 0.001), but had no appreciable effect on bilirubin and alkaline phosphatase levels. Both SSG and MA decreased blood glucose levels (P less than 0.01) and induced proteinuria.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1354978     DOI: 10.1177/096032719201100409

Source DB:  PubMed          Journal:  Hum Exp Toxicol        ISSN: 0960-3271            Impact factor:   2.903


  5 in total

1.  Antimony and health.

Authors:  F A De Wolff
Journal:  BMJ       Date:  1995-05-13

2.  Associations of multiple metals with kidney outcomes in lead workers.

Authors:  Rebecca Shelley; Nam-Soo Kim; Patrick Parsons; Byung-Kook Lee; Bernard Jaar; Jeffrey Fadrowski; Jacqueline Agnew; Genevieve M Matanoski; Brian S Schwartz; Amy Steuerwald; Andrew Todd; David Simon; Virginia M Weaver
Journal:  Occup Environ Med       Date:  2012-07-26       Impact factor: 4.402

3.  Pharmacokinetics, toxicities, and efficacies of sodium stibogluconate formulations after intravenous administration in animals.

Authors:  J Nieto; J Alvar; A B Mullen; K C Carter; C Rodríguez; M I San Andrés; M D San Andrés; A J Baillie; F González
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

4.  Preclinical Studies Evaluating Subacute Toxicity and Therapeutic Efficacy of LQB-118 in Experimental Visceral Leishmaniasis.

Authors:  Edézio Ferreira Cunha-Júnior; Thiago Martino Martins; Marilene Marcuzzo Canto-Cavalheiro; Paulo Roberto Marques; Elyzabeth Avvad Portari; Marsen Garcia Pinto Coelho; Chaquip Daher Netto; Paulo Roberto Ribeiro Costa; Katia Costa de Carvalho Sabino; Eduardo Caio Torres-Santos
Journal:  Antimicrob Agents Chemother       Date:  2016-05-23       Impact factor: 5.191

5.  Immucillins ImmA and ImmH Are Effective and Non-toxic in the Treatment of Experimental Visceral Leishmaniasis.

Authors:  Elisangela Oliveira Freitas; Dirlei Nico; Marcus Vinícius Alves-Silva; Alexandre Morrot; Keith Clinch; Gary B Evans; Peter C Tyler; Vern L Schramm; Clarisa B Palatnik-de-Sousa
Journal:  PLoS Negl Trop Dis       Date:  2015-12-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.